Brokerages Expect Reata Pharmaceuticals Inc (RETA) Will Post Earnings of -$0.58 Per Share

Brokerages expect Reata Pharmaceuticals Inc (NASDAQ:RETA) to report earnings of ($0.58) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Reata Pharmaceuticals’ earnings, with estimates ranging from ($0.82) to ($0.46). Reata Pharmaceuticals reported earnings per share of ($0.19) during the same quarter last year, which would indicate a negative year over year growth rate of 205.3%. The firm is expected to issue its next earnings results on Friday, March 2nd.

On average, analysts expect that Reata Pharmaceuticals will report full year earnings of ($1.91) per share for the current fiscal year, with EPS estimates ranging from ($2.20) to ($1.74). For the next fiscal year, analysts anticipate that the business will report earnings of ($2.36) per share, with EPS estimates ranging from ($2.97) to ($1.58). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Reata Pharmaceuticals.

Reata Pharmaceuticals (NASDAQ:RETA) last posted its earnings results on Monday, November 13th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.11). The business had revenue of $12.60 million during the quarter, compared to analysts’ expectations of $12.54 million. The firm’s revenue was up .0% compared to the same quarter last year.

RETA has been the subject of a number of research analyst reports. Jefferies Group reissued a “buy” rating and issued a $44.00 target price on shares of Reata Pharmaceuticals in a research note on Friday, October 6th. ValuEngine cut Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Zacks Investment Research raised Reata Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 24th. Robert W. Baird reissued a “buy” rating and issued a $47.00 target price on shares of Reata Pharmaceuticals in a research note on Tuesday, October 24th. Finally, Cowen reissued a “buy” rating on shares of Reata Pharmaceuticals in a research note on Tuesday, November 14th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company’s stock. Reata Pharmaceuticals has an average rating of “Buy” and an average price target of $54.71.

In other news, Director James Edward Bass acquired 3,888 shares of Reata Pharmaceuticals stock in a transaction dated Wednesday, November 15th. The stock was bought at an average cost of $24.02 per share, with a total value of $93,389.76. Following the completion of the transaction, the director now directly owns 52,089 shares of the company’s stock, valued at $1,251,177.78. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder James W. Traweek, Jr. acquired 121,725 shares of Reata Pharmaceuticals stock in a transaction dated Wednesday, December 13th. The shares were purchased at an average cost of $24.88 per share, with a total value of $3,028,518.00. Following the completion of the transaction, the insider now directly owns 35 shares of the company’s stock, valued at $870.80. The disclosure for this purchase can be found here. Insiders have bought 413,813 shares of company stock valued at $10,453,354 over the last ninety days. 44.00% of the stock is owned by insiders.

Several hedge funds have recently bought and sold shares of RETA. Sphera Funds Management LTD. acquired a new position in shares of Reata Pharmaceuticals during the third quarter worth about $6,376,000. Emerald Mutual Fund Advisers Trust boosted its position in Reata Pharmaceuticals by 60.9% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 473,051 shares of the company’s stock valued at $14,712,000 after purchasing an additional 179,124 shares during the last quarter. FMR LLC boosted its position in Reata Pharmaceuticals by 74.4% during the second quarter. FMR LLC now owns 414,491 shares of the company’s stock valued at $13,114,000 after purchasing an additional 176,885 shares during the last quarter. Emerald Advisers Inc. PA boosted its position in Reata Pharmaceuticals by 40.1% during the third quarter. Emerald Advisers Inc. PA now owns 569,416 shares of the company’s stock valued at $17,709,000 after purchasing an additional 162,990 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Reata Pharmaceuticals by 109.6% during the second quarter. Vanguard Group Inc. now owns 295,540 shares of the company’s stock valued at $9,350,000 after purchasing an additional 154,515 shares during the last quarter. 29.49% of the stock is owned by institutional investors.

Reata Pharmaceuticals (RETA) traded up $0.26 during trading hours on Monday, reaching $30.21. The company’s stock had a trading volume of 119,249 shares, compared to its average volume of 149,652. Reata Pharmaceuticals has a 1 year low of $19.48 and a 1 year high of $40.88. The company has a current ratio of 3.18, a quick ratio of 3.18 and a debt-to-equity ratio of -0.15. The firm has a market capitalization of $782.08, a PE ratio of -19.75 and a beta of -3.11.

TRADEMARK VIOLATION NOTICE: This article was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/01/29/brokerages-expect-reata-pharmaceuticals-inc-reta-will-post-earnings-of-0-58-per-share.html.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.

Get a free copy of the Zacks research report on Reata Pharmaceuticals (RETA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply